Veerhealth Care Ltd

From a 52-week low of Rs 16.70 to a fresh high of Rs 29.75 on 19 Jun 2026, Veerhealth Care Ltd has surged 78.7% over the past year, significantly outperforming the Sensex, which declined 5.73% in the same period. This rally is underpinned by a strong alignment of technical indicators across multiple timeframes, signalling robust price momentum despite a broadly negative market backdrop.

Veerhealth Care Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 20 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 June 2026, providing investors with an up-to-date view of the company’s performance and prospects.

Veerhealth Care Ltd has surged to a fresh 52-week high of Rs 29.49 on 18 Jun 2026, marking a remarkable 61.11% gain over the past year compared to the Sensex’s decline of 5.18%. This milestone caps a sustained rally fuelled by robust technical momentum and consistent price strength across multiple timeframes.

Veerhealth Care Ltd has surged to a new 52-week high of Rs 27 on 17 Jun 2026, marking a significant milestone after a sustained rally that has delivered a 49.03% return over the past year, comfortably outperforming the Sensex’s decline of 5.53% during the same period.

Veerhealth Care Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a significant shift in its valuation parameters, moving from an expensive to a very expensive rating. Despite this, the stock has delivered robust returns well above the Sensex over multiple time horizons, prompting a reassessment of its price attractiveness and investment potential.

Surging past its previous peak, Veerhealth Care Ltd reached a fresh 52-week high of Rs 26.44 on 16 Jun 2026, marking a significant milestone in its price journey. This advance comes amid a backdrop of strong technical momentum and sustained outperformance relative to its sector and the broader market.

With a decisive surge to Rs 26 on 15 Jun 2026, Veerhealth Care Ltd has reached a fresh 52-week high, marking a 45.46% gain over the past year and significantly outperforming the Sensex, which declined 5.46% during the same period. This milestone reflects a strong technical momentum that has propelled the micro-cap pharmaceutical stock well above its 52-week low of Rs 16.7.

From a 52-week low of Rs 16.25 to a fresh high of Rs 25, Veerhealth Care Ltd has surged 39.7% over the past year, significantly outperforming the Sensex which declined 10.7% in the same period. This rally culminated in the stock hitting its new 52-week peak on 11 Jun 2026, driven by a confluence of strong technical signals and sustained price momentum.

Veerhealth Care Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an expensive to a very expensive rating. Despite this, the stock has delivered robust returns significantly outperforming the Sensex over multiple time horizons, prompting a reassessment of its price attractiveness and investment potential.

Veerhealth Care Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 20 April 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock's current position as of 04 June 2026, providing investors with the latest insights into its performance and outlook.

Veerhealth Care Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects evolving market perceptions and invites a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical trends and peer benchmarks.

With a 65.00% gain over the past year, Veerhealth Care Ltd has surged past its previous 52-week high to close at Rs 24.94 on 2 Jun 2026, marking a significant milestone amid a broader market that remains subdued.

Veerhealth Care Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹48.42 crores, reported a dramatic revenue surge in Q4 FY26 even as profitability turned negative, raising questions about the sustainability of its recent operational momentum. The company posted a net loss of ₹0.35 crores in the March 2026 quarter, a sharp reversal from the ₹0.40 crores profit recorded in the preceding quarter, despite net sales surging 130.85% quarter-on-quarter to ₹16.76 crores.

With a 63.11% gain over the past year, Veerhealth Care Ltd has surged past its previous 52-week high to close at Rs 24.8 on 1 Jun 2026, significantly outperforming the Sensex which declined 8.05% over the same period. This milestone caps a sustained rally fuelled by strong technical momentum and broad-based indicator alignment.